Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
BACKGROUND: mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. METHODS: We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. RESULTS: Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol per liter]), whereas patients receiving placebo had an 18% increase in mean triglyceride levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) (95% CI, -301.0 to 486 mg per deciliter [-3.4 to 5.5 mmol per liter]) (P<0.001). At 3 months, 77% of the patients in the volanesorsen group, as compared with 10% of patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter (8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients who received placebo had such reactions. No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who had levels below 25,000 per microliter. No patient had platelet counts below 50,000 per microliter after enhanced platelet-monitoring began. CONCLUSIONS: Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 15 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data show that volanesorsenmediated lowering of apolipoprotein C-III effectively enhances clearance of triglyceride-rich lipoproteins in patients without LPL activity.27”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Partly supportedcites [27] matched to “ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors” (2016) sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) states that volanesorsen 'dramatically lowered elevated plasma TG levels in patients who have genetic defects in LPL (familial chylomicronemia syndrome [FCS])' and that, despite the absence of a placebo control group, 'this finding suggests that ApoC-III impairs TG clearance predominantly in an LPL-independent fashion'; the Discussion adds that their mouse data are 'consistent with the recent observation that targeting of ApoC-III effectively reduces plasma TGs in LPL-deficient patients'. So the enhanced-clearance-in-LPL-deficient-patients reading is present, but the source hedges it as a suggestion inferred from TG lowering (clearance itself was measured only in mice) and explicitly flags the uncontrolled design; the Discussion also notes the FCS subjects had a mutated LPL with possible residual activity rather than a strict absence. The citing sentence's unhedged 'these data show ... effectively enhances clearance' therefore overstates what this source attributes to the trial. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Not checked yetcites [6] matched to “Chylomicronaemia–current diagnosis and future therapies” (2015) source
- Could not verifycites [21] matched to “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2” (2015) sourceExperimental — accuracy not yet measured
Our copy of the NLA Part 2 recommendations contains no mention of volanesorsen, apolipoprotein C-III as a therapeutic target, or the APPROACH trial (searched: 'volanesorsen APPROACH trial apolipoprotein C-III familial chylomicronemia syndrome', 'apolipoprotein C-III antisense oligonucleotide new therapies', 'severe hypertriglyceridemia pancreatitis threshold'). The closest passages cover only established therapy for very high TG — the 'Dietary considerations for management of hypertriglyceridemia' and 'Targets of lifestyle therapies' sections set the pancreatitis-prevention goal at lowering TG to <500 mg/dL (noting chylomicronemia is often present at ≥750 mg/dL), and the 'Non-statin recommendations' / 'Fibrates' sections discuss fenofibrate and prescription omega-3s — so nothing here speaks to the trial result attributed to this source. Our copy is also flagged as truncated, so the decisive text may be missing. (LLM, conf=0.72)
- Could not verifycites [22] matched to “Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline” (2012) sourceExperimental — accuracy not yet measured
Our copy of the 2012 Endocrine Society guideline contains no mention of volanesorsen, the APPROACH trial, or an antisense apoC-III oligonucleotide (searched: 'volanesorsen APPROACH trial apolipoprotein C-III antisense', 'antisense oligonucleotide apoC-III inhibitor', '750 mg/dl triglyceride threshold'); apoC-III appears only in pathophysiology/kinetics references. Nor does it give a 750-880 mg/dl pancreatitis threshold: the Chylomicronemia syndrome section states pancreatitis risk 'markedly increases with very severe triglyceride levels above 2000 mg/dl' and 'can be prevented by maintaining triglyceride levels below 1000 mg/dl', and the Fibrates section sets a treatment goal of <1000 mg/dl. The trial result attributed here is therefore not addressed by this source at all (the guideline predates the APPROACH trial), so the claim cannot be checked against it. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“findings that support the hypothesis that apolipoprotein C-III also inhibits an LPL-independent pathway of triglyceride-rich lipoprotein clearance.16”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > F
What the sources say
- Supportedcites [16] matched to “Targeting APOC3 in the familial chylomicronemia syndrome” (2014) source
The Discussion says the study's findings suggest that APOC3 regulates triglyceride-rich lipoprotein metabolism through LPL-independent pathways. The Figure 2 caption states more specifically that APOC3 has an inhibitory role in that pathway, matching the citing sentence's hypothesis. (LLM, conf=0.94)
hedgedstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three other patients with lesser grades (grade 1 or 2) of decreased platelet counts were withdrawn from the trial because of concerns on the part of the site investigators.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourteen patients assigned to volanesorsen, as compared with 2 patients assigned to placebo, did not complete the 52-week trial”
- Also stated in: § 541 · plain
“Fourteen patients in the volanesorsen group discontinued the trial: 9 because of adverse events that occurred during treatment (including 5 who had decreases in platelet counts and 4 because of other drug-related side effects), and 5 primarily because of issues related to requirements of the protocol.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 541 · plain
22 more claims
Create a free account to see all 79 claims and to verify the 23 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are consistent with the observations that LDL cholesterol levels are typically very low (<20 mg per deciliter [0.52 mmol per liter]) and total apolipoprotein B levels are within the low-to-normal range in persons with familial chylomicronemia syndrome. 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous trial involving patients with familial chylomicronemia syndrome, the administration of volanesorsen at a weekly dose of 300 mg per deciliter over a 3-month period was accompanied by reductions in apolipoprotein C-III and triglyceride levels of 84% and 77%, respectively, 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While APPROACH was not powered to detect clinical endpoints, exploratory analyses showed a meaningful reduction in pancreatitis episodes among patients who achieved sustained TG levels below 500 mg/dL— considered by some to be a threshold for pancreatitis risk [44].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its safety profile, particularly the high incidence of thrombocytopenia, has limited broader clinical adoption [115]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced platelet counts below 100 000 per microliter was a common adverse event in the volanesorsen group (15 of 33 patients, two patients with levels < 25 000 per microliter).74”
From Clinical review on triglycerides (2020) · cites this paper as [74]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Abstract
“15 of 33 patients in the volanesorsen group had such levels”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
“confirmed nadir levels below 100,000 per microliter were observed in 16 patients (48%) who received volanesorsen”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“1933 mg per deciliter [22.5 mmol per liter]”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Secondary Efficacy End Points
Reported 22.5 · recomputed 21.82357
Citations
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationIssues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
Research works printed but not linked: 1
- Brunzell JD Deeb SS. Familial lipoprotein lipase deficiency apo CII deficiency and hepatic lipase deficiency. In: Scriver CR Beaudet AL Sly WS et al. eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill 2000:2789-816.
Cited by
Items 101–200 of 673
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A., Yang, Z.-H., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 49
Modern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
Sulfur modification in natural RNA and therapeutic oligonucleotides
Zheng, Y. Y., Wu, Y., Begley, T. J., & Sheng, J. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00038a · Cited by 57
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01525-5 · Cited by 57
“become obese and diabetics [1], the emergence of novel and costly therapies to lower triglyceride concentrations, will require better risk based prioritisation [2].”
BackgroundSelf-citationLipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 62
“Volanesorsen APOC3 Antisense oligonucleotide APPROACH TG: 77% reduction at 3 months (baseline 2,267→590 mg/dL) Phase 3 Thrombocytopenia, injection site reactions [29]”
BackgroundProhaska, T. A., Alexander, V. J., Karwatowska-Prokopczuk, E., Tami, J., Xia, S., Witztum, J. L., & Tsimikas, S. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.04.007 · Cited by 46
Self-citationApolipoprotein C3: form begets function
Bornfeldt, K. E. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 45
10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes
Belhassen, M., Van Ganse, E., Nolin, M., Bérard, M., Bada, H., Bruckert, E., Krempf, M., Rebours, V., Valero, R., & Moulin, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa838 · Cited by 47
Heidemann, B. E., Koopal, C., Bots, M. L., Asselbergs, F. W., Westerink, J., & Visseren, F. L. J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.030 · Cited by 48
Witztum, J. L., Gaudet, D., Arca, M., Jones, A., Soran, H., Gouni-Berthold, I., Stroes, E. S. G., Alexander, V. J., Jones, R., Watts, L., et al. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.03.007 · Cited by 44
Self-citationBashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 52
Self-citation2024 FDA TIDES (Peptides and Oligonucleotides) Harvest
Musaimi, O. A., Shaer, D. A., de la Torre, B. G., & Alberício, F. (2025) · Pharmaceuticals · doi:10.3390/ph18030291 · Cited by 51
“Volanesorsen treatment led to thrombocytopenia in approximately 45% of patients, with 6% experiencing severe platelet reductions below 25,000 per µ L, though platelet counts recovered after discontinuation of the drug [35].”
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Bejar, N., Tat, T. T., & Kiss, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01007-9 · Cited by 46
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 47
Drexel, H., LARCHER, B., MADER, A., Vonbank, A., Heinzle, C. F., Moser, B., Zanolin-Purin, D., & Saely, C. H. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.010 · Cited by 46
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
Nucleic Acid–Based Therapies for Atherosclerosis
Mäkinen, P., Ruotsalainen, A.-K., & Ylä-Herttuala, S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0826-2 · Cited by 42
Antisense oligonucleotide based therapeutics and its applications against bacterial infections
Angrish, N., & Khare, G. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100166 · Cited by 44
Wang, H., Huang, X., Xu, P., Liu, X., Zhou, Z., Wang, F., Li, J., Wang, Y., Xian, X., Liu, C., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154740 · Cited by 43
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 48
“Thephase3 APPROACH trial demonstrated that subcutaneous treatment with vola-nesorsen resulted in a signi fi cant reduction in mean plasma triglyceride levels, in patients with FCS 130,131 .”
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
Caddeo, A. M., & Romeo, S. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0438 · Cited by 47
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Fogacci, F., Norata, G. D., Toth, P. P., Arca, M., & Cicero, A. F. G. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00836-w · Cited by 42
“…of participants, personnel and outcome assessment Incomplete outcome data Selective outcome reporting Other potential threats to validity Witztum, 2019 [28••] L L L H H L Digenio, 2016 [29] L L L H H U Gaudet, 2015 [30] L L L H H U H, high risk of bias; L, low risk of bias; U, unclear…”
BackgroundSelf-citationStolte, B., Nonnemacher, M., Kizina, K., Bolz, S., Totzeck, A., Thimm, A., Wagner, B., Deuschl, C., Kleinschnitz, C., & Hagenacker, T. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10569-8 · Cited by 42
“In another study, severe thrombocytopenia was found in 2 of 33 patients with familial chylomicronemia treated with volanesorsen [40].”
BackgroundHypertriglyceridaemia: an update
Wierzbicki, A. S., Kim, E. J., Esan, O., & Ramachandran, R. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207719 · Cited by 51
Jones, A., Peers, K., Wierzbicki, A. S., Ramachandran, R., Mansfield, M., Dawson, C., Ochoa-Ferraro, A., Soran, H., Jenkinson, F., McDowell, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.008 · Cited by 39
“In the APPROACH studies, thrombocytopenia was the most significant volanesorsen-related AE [12].”
Self-citationProtein-based delivery systems for RNA delivery
Zhu, H., Luo, H., Chang, R., Yang, Y., Liu, D., Ji, Y. R., Qin, H., Rong, H., & Yin, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.032 · Cited by 40
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
“Severe HTG in Familial Chylomicronemia syndrome (FCS), with plasma TG levels above 886 mg/dl (10 mmol/l), is often caused by either homozygous or compound heterozygous loss of function mutations in genes involved in TG lipolysis, leading to impaired Lipoprotein Lipase (LPL)-mediated lipolysis.”
BackgroundInfluentialSelf-citationApolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 43
Dohrn, M. F., Ihne-Schubert, S. M., Hegenbart, U., Medina, J., Zuchner, S. L., Coelho, T., & Hahn, K. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15233 · Cited by 43
“As mentioned earlier, the most relevant side effect of inotersen was thrombopenia, which might be a class effect as it occurred with volanesorsen, another MOE-ASO, as well (Witztum et al., 2019).”
BackgroundHussain, A., Sun, C., Selvin, E., Nambi, V., Coresh, J., Jia, X., Ballantyne, C. M., & Hoogeveen, R. C. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa152 · Cited by 43
“Novel therapies designed to reduce apoC-III or ANGPTL3 level, and consequently TG/TGRL, are in early-phase trials.(18,19) To provide epidemiological data on whether these novel therapies may be of potential benefit to reduce ASCVD risk in older individuals with increased TGRL levels and high ASCVD risk, we investigate…”
BackgroundGenetics of hypertriglyceridemia and atherosclerosis
Gill, P. K., Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000839 · Cited by 41
Paquette, M., Amyot, J., Fantino, M., Baass, A. W., & Bernard, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab360 · Cited by 41
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 46
Gaudet, D., Gonciarz, M. D., Xi Zhong, S. H. E. N., Leohr, J. K., Beyer, T. P., Day, J. W., Mullins, G. R., Zhen, Y., Hartley, M., Larouche, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03830-4 · Cited by 41
Self-citationTargeting angiotensinogen with RNA-based therapeutics
Ren, L., Colafella, K. M. M., Bovée, D. M., Uijl, E., & Danser, A. H. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000586 · Cited by 40
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
Calcaterra, I., Lupoli, R., Di Minno, A., & Di Minno, M. N. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 37
Deshotels, M. R., Hadley, T. D., Roth, M. M., Agha, A. M., Pulipati, V. P., Nugent, A. K., Virani, S. S., Nambi, V., Moriarty, P. M., Davidson, M. H., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318445 · Cited by 41
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review
Fu, Q., Hu, L., Shen, T., Yang, R., & Jiang, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226773 · Cited by 43
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“…research with modified ASOs, such as GalNAc-conjugated ones, aims to address these concerns and enhance the clinical utility of ApoC-III-targeting ASOs, potentially offering a safe and efficient approach for reducing TG levels in CVD, including familial chylomicronemia syndrome (FCS) [112,113].”
BackgroundReeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 36
Self-citationLipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 46
“ApoC-III Volanesorsen, a 2′-O-(2-methoxyethyl)modified antisense oligonucleotide APPROACH (phase 3) [91] Patients with familial chylomicronemia syndrome • 77% decrease in mean TG levels.”
BackgroundMethodSafety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 36
“This leads to lower apoC-III levels and lower levels of chylomicrons and triglycerides [50].”
BackgroundAntisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
Kim, Y. J., & Krainer, A. R. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2172 · Cited by 39
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Koenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 35
Self-citationChinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
“Clinical research suggests that both the above drugs can reduce TG levels significantly while also reducing non-HDL-C and ApoB levels, [117,118] which is promising for improving overall cardiovascular health.”
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
“[25,27].”
MethodInfluentialSelf-citationParagh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 38
“The most common side effect was a local reaction at the injection site and, in 5 cases, a decrease in platelet count, which necessitated discontinuation of treatment [105].”
BackgroundVolanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
“, injection-site reaction, fatigue, chills, sweating, and generalized erythema) [14].”
BackgroundMethodInfluentialGene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 34
“[38,39], which coincided with a marked decrease in the number of pancreatitis events [39].”
BackgroundSelf-citationVolanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1912350 · Cited by 33
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
“The phase 3 APPROACH trial included 66 patients with genetically confirmed FCS [59].”
Pediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 34
“266 ,267 To address this issue, Olezarsen and ARO-APOC3, GalNAc-bound RNAi agents, are novel agents in development.”
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
“In a phase III clinical trial, the APOC3-targeting antisense nucleotide Volanesorsen reduced ApoC3 plasma levels by 84% without serious adverse events.(36) Similarly, monoclonal antibodies for the inhibition of ApoC3(37) or ApoC3 antagonist peptides(26) are in development.”
BackgroundAdvances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?
Hegele, R. A. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab890 · Cited by 29
Akivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
“The APPROACH trial showed a mean reduction in triglyceride levels of approximately 77% in patients with familial chylomicronemia syndrome [60].”
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 31
“5% of patients in the COMPASS study) [20, 39, 40].”
BackgroundResultInfluentialSelf-citationBchetnia, M., Bouchard, L., Mathieu, J., Campeau, P. M., Morin, C., Brisson, D., Laberge, A., Vézina, H., Gaudet, D., & Laprise, C. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-107809 · Cited by 49
Self-citationGenomics in medicine: A new era in medicine
Pattan, V., Kashyap, R., Bansal, V., Candula, N., Koritala, T., & Surani, S. (2021) · World Journal of Methodology · doi:10.5662/wjm.v11.i5.231 · Cited by 33
Research and Development of Oligonucleotide Therapeutics in Japan for Rare Diseases
Igarashi, J., Niwa, Y., & Sugiyama, D. (2022) · Future Rare Diseases · doi:10.2217/frd-2021-0008 · Cited by 33
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Zimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae090 · Cited by 29
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
“Following the implementation of enhanced plateletmonitoring during the trial, no patients developed platelet counts <50,000 per microL [36].”
BackgroundMethodInfluentialKatsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“A recent fixed-effects meta-analysis on three randomized controlled trials on patients with HTG > 500mg/dL reported a significant reduction in the incidence of AP in volanesorsen group compared to placebo (OR 0.18; 95 % CI 0.04-0.82) [105,106,108, 109].”
BackgroundMethodInfluentialRemnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 30
“The APPROACH trial demonstrated that volanesorsen reduced TG levels by 77% compared to an 18% increase in the placebo group among patients with familial chylomicrone-mia syndrome and plasma TG > 500 mg/dL [57].”
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 27
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
Self-citationGreve, A. M., Wulff, A. B., Bojesen, S. E., & Nordestgaard, B. G. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae089 · Cited by 27
Bashir, B., Downie, P., Forrester, N. A., Wierzbicki, A. S., Dawson, C., Jones, A., Jenkinson, F., Mansfield, M. W., Datta, D. B. N., Delaney, H., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320955 · Cited by 26
Self-citationManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“syndrome (FCS) and other forms of severe hypertriglyceridemia, but it has been associated with thrombocytopenia [132].”
BackgroundAssessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
Henry, S. P., Arfvidsson, C., Arrington, J., Canadi, J., CROWE, D. F., Gupta, S., Lohmann, S., Massonnet, B., Mytych, D. T., Rogers, T., et al. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0112 · Cited by 27
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 27
“In the phase 3 APPROACH trial, conducted on with severe hypertriglyceridemia, volanesorsen induced an 84% reduction in apoC3 within 3 months of treatment respectively [37].”
BackgroundClinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma
Khuu, A., Verreault, M., Colin, P., Tran, H., & Idbaïh, A. (2024) · Cells · doi:10.3390/cells13221869 · Cited by 28
“This results in decreased tissue accumulation, primarily in the kidneys and liver, and reduced bioavailability, with distribution half-lives of approximately ten minutes in rats and mice [66–69].”
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 26
“After completion of the above study, 22 FCS patients entered an open-label extension trial called ReFOCUS, in which every participant received volanesorsen for a median of 222 days [59].”
BackgroundMethodInfluentialResidual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 31
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 25
Self-citationEfficacy and safety of lomitapide in familial chylomicronaemia syndrome
Cefalu, A. B., D’Erasmo, L., Iannuzzo, G., Noto, D., Giammanco, A., Montali, A., Zambon, A., Forte, F., Suppressa, P., Giannini, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.017 · Cited by 24
Self-citationAtherosclerosis: cell biology and lipoproteins
Getz, G. S., & Reardon, C. A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000704 · Cited by 27
“more than 50% [13] suggesting that apoC-III also influences an LPL independent pathway to control plasma triglyceride levels.”
BackgroundPandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Gagnon, É., & Arsenault, B. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117501 · Cited by 24
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan, D. C., & Watts, G. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000920 · Cited by 24
Lipolytic enzymes and free fatty acids at the endothelial interface
Goldberg, I. J., Cabodevilla, A. G., Samovski, D., Cifarelli, V., Basu, D., & Abumrad, N. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.018 · Cited by 25
Prevalence of familial chylomicronemia syndrome in a quaternary care center
Pallazola, V. A., Sajja, A. P., Derenbecker, R., Ogunmoroti, O., Park, J., Sathiyakumar, V., & Martin, S. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319888054 · Cited by 24
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 29
“For example, results from the APPROACH trial, a 52-week randomized, double-blind, phase 3 in 66 patients with familial chylomicronemia syndrome, demonstrated that the drug resulted in an impressive 77% decrease in plasma triglyceride levels (Witztum et al. 2019).”
ResultRecent advances in regulating lipid metabolism to prevent coronary heart disease
Du, J., Wu, W., Zhu, B., Tao, W., Liu, L., Cheng, X., Zhao, M., Wu, J., Li, Y., & Pei, K. (2023) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2023.105325 · Cited by 27
Metadata
- Authors
- Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., Stroes, E. S. G., Bergeron, J., Soran, H., Civeira, F., Hemphill, L., Tsimikas, S., Blom, D. J., O’Dea, L., & Bruckert, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- From the Department of Medicine, University of California San Diego, La Jolla (J.L.W., S.T.), and Ionis Pharmaceuticals, Carlsbad (V.J.A., Q.Y., S.G.H., R.S.G., S.T.) — both in California; the Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, QC (D.G.), and the Department of Medicine and Laboratory Medicine, Centre Hospitalier Universitaire de Québec–University Laval, Quebec, QC (J.B.) — both in Canada; the Department of Medicine, Beth Israel Deaconess Medical Center (S.D.F....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-08
- Volume
- 381
- Issue
- 6
- Pages
- 531-542
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2966503756
- Semantic Scholar
- 1b419fba1e6af00f305b1f8b0ee92c239fec7d40
- Cited by
- 669
- References
- 34
- Citations by year
- 2026: 88 · 2025: 112 · 2024: 112 · 2023: 77 · 2022: 95 · 2021: 91 · 2020: 79 · 2019: 14
- FWCI
- 50.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zaguan (University of Zaragoza Repository) (submittedVersion)
- Funders
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, apolipoprotein C-III, triglyceride levels, antisense therapy, hypertriglyceridemia, injection site reactions, platelet count, treatment efficacy and safety, triglyceride lowering
- MeSH terms
- Adult, Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Platelet Count, RNA, Messenger, Thrombocytopenia, Triglycerides, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.